Alterity Therapeutics (ASX:ATH) Presentation, FNN Investor Event, June 2019, Sydney

Company Presentations

Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, presents on the company's lead drug candidate, the potential applications for the drug and the breadth of the market at FNN's Investor Event.

Key points:

  • Share price up approx 3 per cent year to date.
  • Dual-listed company formerly known as Prana Biotechnology.
  • Lead drug has orphan drug status for the treatment of Multiple System Atrophy.
  • Strong leadership team with proven track record obtaining US FDA approvals.

For more, watch CEO and Chairman, Geoffrey Kempler present 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.